Journal of Endocrinological Investigation

, Volume 21, Issue 10, pp 694–698 | Cite as

Effect of finasteride in idiopathic hirsutism

  • Emanuela Faloia
  • S. Filipponi
  • V. Mancini
  • S. Di Marco
  • F. Mantero


Increased 5α-reductase activity has been found in hair follicles of hirsute women, suggesting a pathogenetic role. The aim of the present study was to evaluate the effect of finasteride in the treatment of idiopathic hirsutism. Twenty-seven women with idiopathic hirsutism, aged 16–35 years, were treated for 6 months with finasteride, 5 mg once daily. Fourteen patients were on finasteride alone (group A), while the remaining received in addition an oral contraceptive (group B). Clinical, hormonal and biochemical evaluation were performed before, and after 3 and 6 months of treatment. Clinical evaluation was repeated 6 months after drug discontinuation in seven patients. Treatment was well tolerated by all patients; no side effects or adverse reactions were reported. A significant improvement of hirsutism was obtained by finasteride; clinical score observed at the 6th month of therapy was reduced from 11.71 ±2.23 to 7.92±1.81 (p<0.05) and from 14.92±6.13 to 9.3±2.75 (p<0.05) in group A and B, respectively. Clinical score in seven patients was still 8.61 ±2.28 (p<0.05) 6 months after the end of therapy. Finasteride treatment alone (group A) induced a slight increase, though not significant, in serum androgens; DHT and SHBG did not change. In group B (finasteride plus oral contraceptive) total testosterone and free testosterone showed no significant decrease; after 6 months of therapy DHT was reduced significantly, while SHBG levels were increased. These data demonstrate that 5α-reductase inhibition may be an effective treatment in women suffering from idiopathic hirsutism. This approach may be attractive due to the absence of adverse reactions, although the necessity of an adequate contraception should be kept in mind.


Hirsutism antiandrogens 5α-reductase finasteride 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Biffignandi P., Massucchetti C., Molinatti G.M. Female hirsutism: pathophysiological consideration and therapeutic implications. Endocr. Rev. 5: 498, 1984.PubMedCrossRefGoogle Scholar
  2. 2.
    Erkkola R., Ruutiainen K. Hirsutism: definitions and etiology. Ann. Med. 22: 99, 1990.PubMedCrossRefGoogle Scholar
  3. 3.
    Serafini P., Lobo R.A. Increased 5α-reductase activity in idiopathic hirsutism women. J. Clin. Endocrinol. Metab. 43: 74, 1985.Google Scholar
  4. 4.
    Labrie F., Sugimoto Y., Luu-The V., Simard J., Lachance Y., Bachvarov D., Leblanc G., Durosher F., Paquet N. Structure of human type II 5α-reductase gene. Endocrinology 131: 1571, 1992.PubMedGoogle Scholar
  5. 5.
    Thigpen A.E., Silver R.I., Guileyardo J.M., Casey M.L., McConnell J.D., Russel D.W. Tissue distribution and ontogeny of steroid 5α-reducstase isozyme expression. J. Clin. Invest. 92: 903, 1993.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Wilson J.D., Griffin J.E., Russel D.W. Steroid 5α-reductase 2 deficiency. Endocr. Rev. 14: 577, 1993.PubMedGoogle Scholar
  7. 7.
    Thigpen A.E., Davis D.L., Gautier T., Imperato McGinley J., Russel DW. Brief Report: the molecular basis of steroid 5α-reductase deficiency in a large dominican kindred. N. Engl. J. Med. 327: 1216, 1992.PubMedCrossRefGoogle Scholar
  8. 8.
    Peters D.H., Sorkin E.M. Finasteride. Drugs 46: 177, 1993.PubMedCrossRefGoogle Scholar
  9. 9.
    Ferriman D., Gallwey J.D. Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab. 21: 1440, 1961.PubMedCrossRefGoogle Scholar
  10. 10.
    Carr B.R., Breslau N.A., Givens C., Byrd W., Barnett-Hamm C., Marshburn P.B. Oral contraceptive pills, Gonadotropin-Releasing Hormone Agonist, or use in combination for treatment of hirsutism: a clinical research center study. J. Clin. Endocrinol. Metab. 80: 1169, 1995.PubMedGoogle Scholar
  11. 11.
    Spritzer P., Billaud L., Thalabard J.C., Birman P., Mowszowicz I., Raux-Demay MC., Clair F., Kuttenn F., Mauvais-Jarvis P. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J. Clin. Endocrinol. Metab. 70: 642, 1990.PubMedCrossRefGoogle Scholar
  12. 12.
    Cusan L., Dupont A., Gomez J.-L., Tremblay R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil. Steril. 61: 281, 1994.PubMedGoogle Scholar
  13. 13.
    O’Brien R.C., Cooper M.E., Murray R.M.L., Seeman E., Thomas A.K., Jerums G. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism. J. Clin. Endocrinol. Metab. 72: 1008, 1991.PubMedCrossRefGoogle Scholar
  14. 14.
    Nielsen P.G. Treatment of idiopathic hirsutism with spironolactone. Dermatologica 165: 194, 1982.CrossRefGoogle Scholar
  15. 15.
    Jones K.R., Katz M., Keyzer C., Gordon W. Effect of cyproterone acetate on rate of hair growth in hirsute females. Br. J. Dermatol. 105: 685, 1981.PubMedCrossRefGoogle Scholar
  16. 16.
    Helfer E.L., Miller J.C., Rose L.I. Side effects of spironolactone therapy in the hirsute women. J. Clin. Endocrinol. Metab. 66: 208, 1988.PubMedCrossRefGoogle Scholar
  17. 17.
    Wysowki D.K., Frieman J.P., Tourtelot J.B., Horton M.L. Fatal and non fatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118: 860, 1993.CrossRefGoogle Scholar
  18. 18.
    Wallace C., Lalor E.A., Chik C.L. Hepatotoxicity complicating Flutamide treatment of hirsutism. Ann. Intern. Med. 119: 1150, 1993.PubMedCrossRefGoogle Scholar
  19. 19.
    Faloia E., Filipponi S., Mancini V., Morosini P., De Pirro R. Treatment with a gonadotropin-releasing hormone agonist in acne or idiopathic hirsutism. J. Endocrinol. Invest. 16: 675, 1993.PubMedCrossRefGoogle Scholar
  20. 20.
    Andreiko J.L., Monroe S.E., Jaffe R.B. Treatment of hirsutism with a gonadotropin-releasing hormon agonist (nafarelin). J. Clin. Endocrinol. Metab. 63: 854, 1986.CrossRefGoogle Scholar
  21. 21.
    Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 67: 701, 1988.PubMedCrossRefGoogle Scholar
  22. 22.
    Mellin T.N., Busch R.D., Rasmusson G.H. Azasteroid as inhibitors of testosterone 5α-reductase in mammalian skin. J. Steroid. Biochem. Mol. Biol. 44: 121, 1993.PubMedCrossRefGoogle Scholar
  23. 23.
    Dallob A.L., Sadich N.S., Unger W., Lipert S., Geissler L.A., Gregoir S.L., Nguyen H.H., Moore E.C., Tanaka W.K. The effect of finasteride, a 5α-reductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J. Clin. Endocrinol. Metab. 79: 703, 1994.PubMedGoogle Scholar
  24. 24.
    Fruzzetti F., De Lorenzo D., Parrini D., Ricci G. Effect of finasteride, a 5α-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J. Clin. Endocrinol. Metab. 79: 831, 1994.PubMedGoogle Scholar
  25. 25.
    Wong I.L., Morris R.S., Chang L., Spahn M.A., Stanczyk F.Z., Lobo R.A. A prospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J. Clin. Endocrinol. Metab. 80: 233, 1995.PubMedGoogle Scholar
  26. 26.
    Moghetti P., Castello R., Magnani C.M., Tosi F., Negri C., Armanini D., Bellotti G., Muggeo M. Clinical and hormonal effect of the 5α-reductase inhibitor finasteride in hirsutism. J. Clin. Endocrinol. Metab. 79: 1115, 1994.PubMedGoogle Scholar
  27. 27.
    Toscano V., Horton R. Circulating Dihydrotestosterone may not reflect peripheral formation. J. Clin. Invest. 79: 1653, 1987.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Ciotta L., Cianci A., Calogero A.E., Palumbo M.A., Marietta E., Sciuto A., Palumbo G. Clinical and endocrine effects of finasteride, a 5α-reductase inhibitor, in women with idiopathic hirsutism. Fertil. Steril. 64: 299, 1995.PubMedGoogle Scholar
  29. 29.
    Tolino A., Petrone A., Sarnacchiaro F., Cirillo D., Ronsini S., Lombardi G., Nappi C. Finasteride in the treatment of hirsutism: new therapeutic perspectives. Fertil. Steril. 66: 61, 1996.PubMedGoogle Scholar
  30. 30.
    Castello R., Tosi F., Perrone F., Negri C., Muggeo M., Moghetti P. Outcome of long-term treatment with the 5α-reductase inhibitor finasteride in idiopathic hirsutism: clinical and hormonal efects during a 1-year course of therapy and 1-year follow-up. Fertil. Steril. 66: 734, 1996.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1998

Authors and Affiliations

  • Emanuela Faloia
    • 1
  • S. Filipponi
    • 1
  • V. Mancini
    • 1
  • S. Di Marco
    • 1
  • F. Mantero
    • 1
  1. 1.Clinica di Endocrinologia, Istituto di Medicina ClinicaUniversity of AnconaAnconaItaly

Personalised recommendations